Search results
Results From The WOW.Com Content Network
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating ...
Inovio Pharmaceuticals reported total revenue for its fourth quarter of $8.8 million, a 3.5% gain compared to the year-ago quarter of $8.5 million. Inovio Pharmaceuticals Inc (INO) Q4 Revenue Grew ...
Inovio's net loss for the third quarter of 2024 was $25.2 million, or $0.89 per share, basic and dilutive, compared to a net loss of $33.9 million, or $1.52 per share, basic and dilutive, for the ...
Glassdoor is an American website where current and former employees anonymously review companies, operated by the company of the same name. [ 1 ] In 2018, the company was acquired by the Japanese Recruit Holdings (Owner of Indeed ) for US$1.2 billion, and it continues to operate as an independent subsidiary.
The stock of Inovio Pharmaceuticals (NAS:INO, 30-year Financials) shows every sign of being fairly valued, according to GuruFocus Value calculation.
That same month, the company's MedImmune subsidiary acquired exclusive rights to Inovio Pharmaceuticals' INO-3112 immunotherapy under an agreement which could net more than US$727.5 million for Inovio. INO-3112 targets Human papillomavirus types 16 and 18. [58] In September, Valeant licensed Brodalumab from the company for up to US$445 million.
During Q2, Inovio Pharmaceuticals's (NASDAQ: INO) reported sales totaled $267.19 thousand. Despite a 15.17% in earnings, the company posted a loss of $29.06 million. In Q1, Inovio Pharmaceuticals ...
On 26 August 2021 Inovio's global Phase 3 efficacy trial receives authorization to proceed from Brazil. [10] On 26 October 2021 The World Health Organization launched a Global Covid-19 Trial termed as the Solidarity Trial Vaccines. Inovio INO-4800 was chosen as the first DNA Vaccine to be introduced in the largest vaccine trial in history.